Biotech venture creation is a team sport. Atlas brings together talented entrepreneurs with experience in research, development, deal making, and finance to build value in breakthrough biotech companies.

Entrepreneurs-in-Residence, Venture Partners, and Atlas Advisors

Nessan Bermingham, PhD

Atlas Advisor; Chief Executive Officer, Intellia Therapeutics


Nessan is co-founder and chief executive officer of Intellia Therapeutics. He has over ten years of experience in life science investing across venture, secondary, and public markets. Prior to joining Atlas Venture, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical, and sits on the advisory board of the California Institute for Regenerative Medicine.

Stuart Chaffee, PhD

Entrepreneur-in-Residence


Stuart is an EIR with Atlas. He joined from Biogen where he spent five years in a number of different roles across finance, business development, program leadership and corporate strategy.  Prior to Biogen, Stuart was at Leerink Parnters, a healthcare focused investment bank, and was part of the founding team at Zafgen, a publicly traded obesity therapeutics company.  Originally trained as a synthetic organic chemist, Stuart started his career as a medicinal chemist at Amgen where he led a number of drug discovery and development programs focused in oncology and neurodegenerative diseases.  Stuart was educated at The College of William and Mary, Yale University, and The University of Pennsylvania.

Michael Curtis, PhD

Entrepreneur-in-Residence; Chief Development Officer, Ataxion


Mike is chief development officer of Ataxion. Prior to joining Atlas Venture and Ataxion, Mike spent over twenty years in pharma, including in research and development roles at Bristol-Myers Squibb and Infinity Pharmaceuticals. He has led multidisciplinary research and development teams and advanced eight compounds from discovery to clinical studies across several therapeutic areas. In addition, Mike was involved with advancing four compounds through late stage development, resulting in three regulatory approvals.

Rajesh Devraj, PhD

Atlas Advisor


Raj was chief scientific officer of Padlock Therapeutics until its sale to BMS in March 2016. Raj previously served as president and chief executive officer of Euclises Pharmaceuticals and senior vice president of Deciphera Pharmaceuticals. Prior to that, he was senior vice president of Jubilant Drug Discovery & Development. Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies. He has led multiple discovery & early clinical development teams that have advanced eight candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain.

Adam Friedman, MD, PhD

Entrepreneur-in-Residence; Director of Corporate Development, Raze Therapeutics


Adam is a founding team member of Raze Therapeutics, and also worked with the founding team at RaNA Therapeutics. He currently serves as director of corporate development at Raze Therapeutics. He is also a research fellow at Massachusetts General Hospital, and was previously a physician at Boston Children's Hospital after completing his MD and PhD degrees at Harvard Medical School.

Jason Gardner, PhD

Entrepreneur-in-Residence


Jason is an EIR with a passion for translating science to medicines. He was Head of GSK R&D Satellite in Boston, and created and led the Regenerative Medicine Unit where he ran internal programs and established external partnerships, including stem cell gene therapies. Jason was also Head of GSK’s Center of Excellence for External Drug Discovery and led a team that identified, established and managed alliances with world-leading biotech companies. He has worked on multiple successful modalities across a range of therapeutic areas from target to launch, including the NDA approval for Tykerb in breast cancer. He was formerly a scientist at Progenics Pharmaceuticals and Chiron, and was educated at Cambridge, Oxford and Harvard Universities.

Michael Gilman, PhD

Atlas Advisor; Scientific Advisory Board, Raze Therapeutics; Scientific Advisory Board, Obsidian Therapeutics


Mike was chief executive officer of Padlock Therapeutics until its sale to BMS in March 2016. Prior to (re-)joining Atlas Venture in 2013, Mike was the founder and CEO of Atlas portfolio company Stromedix, which was sold to Biogen Idec in 2012. Previously, he led all discovery research activities at Biogen Idec. Before that, Mike served as chief scientific officer of ARIAD Pharmaceuticals and on the scientific staff at Cold Spring Harbor Laboratory.

Gary D. Glick, PhD

Entrepreneur-in-Residence


Gary is an EIR focused on developing new drugs that control inflammatory pathways. In 2006, Gary founded Lycera Corp. to discover breakthrough medicines for autoimmunity and cancer. Under his direction, Lycera partnered three programs with Merck & Co., advanced LYC-30937, a modulator of the mitochondrial ATPase based directly on research from his academic lab, into clinical trials for inflammatory bowel disease, and established and drove Lycera’s immune-oncology platform. Gary trained at Columbia and Harvard and has been on the chemistry faculty at the University of Michigan in Ann Arbor since 1990. He has authored over 100 peer-reviewed papers and is the inventor on 27 issued U.S. patents.

Jeffrey Hatfield

Atlas Advisor; Chief Executive Officer, Vitae Pharmaceuticals


Jeff is president and chief executive officer of Vitae Pharmaceuticals. Prior to joining Vitae Pharmaceuticals, Jeff worked at Bristol-Myers Squibb in a variety of executive positions, including: senior vice president of BMS’s virology and immunology divisions, where he was responsible for all aspects of the $1 billion business; president and general manager, Canada; and vice president, U.S. managed health care. While at BMS, Jeff was directly associated with several product successes, including Pravachol®, Plavix®, Avapro®, Abilify®, Reyataz®, and Atripla®.

Ed Holson, PhD

Entrepreneur-in-Residence; Chief Scientific Officer, KDAC Therapeutics


Ed is the chief scientific officer at KDAC Therapeutics. He is also the director of the medicinal chemistry group in the Stanley Center for Psychiatric Research and a director of chemistry in the Chemical Biology Platform at the Broad Institute. He joined the Stanley Center to design and implement a range of biologic strategies toward developing novel therapies in central nervous system related disorders including schizophrenia, bipolar disorder, and cognitive impairment. Prior to that, Ed worked in medicinal chemistry and pharmaceutical development roles for Infinity Pharmaceuticals and Merck & Co.

Tom Hughes, PhD

Atlas Advisor; Chief Executive Officer, Zafgen


Tom is the chief executive officer of Zafgen. He has over 25 years of experience in pharmaceutical research and development. From 1987 until he joined Zafgen in 2008, Tom held several positions at Novartis AG including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research. Tom has authored over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity. Tom also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Atlas Venture portfolio company Nimbus Therapeutics.

Rosana Kapeller, MD, PhD

Atlas Advisor; Chief Scientific Officer, Nimbus Therapeutics


Rosana is the chief scientific officer of Nimbus Therapeutics and has more than 20 years of leadership experience in the biotechnology industry. Prior to joining Nimbus, she was co-founder and vice president of research of Aileron Therapeutics, where she led the development of “Stapled Peptide” technology. Prior to that, Rosana held positions of increasing responsibility at Millennium Pharmaceuticals, most recently as director, department of molecular and cellular biology. In 2012, Rosana was named one of the Top 20 Women to Watch by Mass High Tech.

Tariq Kassum, MD

Entrepreneur-in-Residence; Head of Business Operations, Obsidian Therapeutics


Tariq is Head of Business Operations at Obsidian Therapeutics. Previously he was Vice President, Business Development and Strategy, for Takeda Oncology, with responsibility for transactions and collaborations, alliance management with key partners, and strategic planning. Previously, he led Takeda’s U.S. corporate development efforts where he managed multiple acquisitions and divestitures. Before that he was a senior analyst covering healthcare equities at Seneca Capital. He began his career as an investment banker with CIBC World Markets serving clients in the biotechnology and specialty pharmaceuticals industries.

Vanessa King, PhD

Entrepreneur-in-Residence; CEO, Luc Therapeutics


Vanessa is chief executive officer of Luc Therapeutics. She previously headed Amgen’s East Coast business development and external venture innovation, following that company’s $415M acquisition of deCODE genetics in December 2012. At deCODE Vanessa led corporate development as part of the founding turnaround team. Before that, Vanessa ran Scientific and Strategic Operations globally at the Novartis Institutes for Biomedical Research, and served as VP Business Development and Strategy at both the J. Craig Venter Institute and PerkinElmer Life and Analytical Sciences, after starting her career as a consultant for McKinsey & Company.

Geoff MacKay

Entrepreneur-in-Residence; President & CEO, AVROBIO


Geoff is president & chief executive officer of AVROBIO. Previously Geoff was CEO of Organogenesis Inc which treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff is board member & interim CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts.

Ankit Mahadevia, MD

Atlas Advisor; President and Chief Executive Officer, Spero Therapeutics


Ankit is co-founder, president, and chief executive officer of Spero Therapeutics. Ankit was previously a venture partner at Atlas Venture. Prior to that, he worked in business development at Genentech, in health policy in Washington, and helped build several early stage biotech companies including Arcion Therapeutics. Ankit obtained his MD from John Hopkins University Medical School and his MBA from Wharton School at the University of Pennsylvania.

Nello Mainolfi, PhD

Entrepreneur-in-Residence; Head of Drug Discovery, Raze Therapeutics


Nello is head of drug discovery at Raze Therapeutics. Before joining Raze, Nello spent almost a decade at the Novartis Institutes for Biomedical Research, where first as team member and then as interdisciplinary project team leader he contributed to the identification of more than 10 compounds that have entered preclinical and clinical development. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver development candidates. Nello has authored multiple peer-reviewed publications; he is co-inventor on several patents and has written reviews in the areas of synthetic chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute.

Mark Manfredi, PhD

Entrepreneur-in-Residence; Chief Scientific Officer, Raze Therapeutics


Mark is Chief Scientific Officer of Raze Therapeutics and has nearly two decades of experience in cancer biology. Mark was previously Vice President, Oncology Biology at Takeda Pharmaceuticals where he led the Oncology Biology group and was a member of the senior R&D management team responsible for the global oncology R&D strategy. During his time at Takeda the Oncology organization put 8 novel mechanisms into the clinic with the most advanced compounds being in phase 3 clinical development. Mark received his BS from the University of Rhode Island and earned his PhD in Biology from Boston College.

William Marshall, PhD

Atlas Advisor; Chief Executive Officer and President, Miragen Therapeutics


Bill is miRagen’s president, chief executive officer, co-founder, and director. Bill was previously vice president of technology and business development for bioscience at Thermo Fisher Scientific where he led the Thermo Fisher Biosciences Division. Prior to that Bill was a scientific founder and executive vice president of Dharmacon, Inc. Earlier, Bill served in many capacities at Amgen, Inc., most recently as associate director of research, site head for research, and head of the nucleic acid and peptide technology department.

Ronald Renaud

Atlas Advisor; Chief Executive Officer, RaNA Therapeutics


Ron is chief executive officer of RaNA Therapeutics. He was previously president and chief executive officer of Idenix Pharmaceuticals, which he refocused on drug discovery and development, resulting in its acquisition by Merck in August 2014. Prior to Idenix, Ron served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, and before that he was a biotechnology equity research analyst at JP Morgan, Schwab Soundview, and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations, and finance.

Adam Rosenberg, JD

Atlas Advisor; President & CEO, Rodin Therapeutics


Adam is president and CEO of Rodin Therapeutics, where he also serves as a member of the Board of Directors.  Adam has co-founded numerous companies, including Teleos Therapeutics, where he is CEO and director, as well as Link Medicine and Clean Membranes.  He has also served in interim executive and strategic advisory roles with numerous healthcare and technology companies, including Brightstar (acquired by SoftBank) and Gecko Health Innovations (acquired by Teva Pharmaceuticals). Previously Adam co-founded Faber Law Group, a boutique business law firm focused on the biotechnology sector, and was a principal with Ovation Capital Partners, an early-stage technology venture fund. 

Saurabh Saha, MD PhD

Venture Partner; Chief Executive Officer, Delinia


Saurabh is chief executive officer of Delinia. He was previously chief medical officer of Synlogic and president of BioMed Valley Discoveries where he led the development and demonstrated human effectiveness of two first-in-class cancer drugs, an ERK inhibitor (Ulixertinib) and a bacteriolytic immunotherapy. In 2005, Saurabh was recruited from McKinsey to become global head of the New Indications Discovery Unit at Novartis. Saurabh published over 70 papers and patents (issued and pending) and sits on the editorial board of six journals. He is an alumnus of Oxford University, Harvard Business School, The Johns Hopkins School of Medicine, and Caltech.

Vipin Suri, PhD

Entrepreneur-in-Residence; Head of Biology, Raze Therapeutics


Vipin is the head of biology of Raze Therapeutics, co-founder of NiDares, and consulting biologist for a number of Atlas Venture seed investments. Prior to joining Atlas, Vipin was director and head of pharmacology at Sirtris, a GlaxoSmithKline company, and before that he worked in the cardiovascular and metabolic diseases group at Pfizer.

Samantha Truex

Atlas Advisor


Sam was chief business officer of Padlock Therapeutics until its sale to BMS in March 2016. She has 20 years of experience in the biotech industry. At Biogen Idec, Sam served as vice president in the corporate development group, and also served as program lead for multiple preclinical and launch-stage products. Prior to Biogen Idec, Sam led licensing and M&A transactions across multiple business units of Genzyme.

George Vlasuk, PhD

Atlas Advisor; Chief Executive Officer, Navitor Pharmaceuticals


George is chief executive officer of Navitor Pharmaceuticals. He is a scientifically trained executive with nearly 30 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. Most recently George served as CEO of Sirtris from 2009 to 2013. Before that, he held various scientific leadership positions at Wyeth, Corvas International, Merck & Co., and California Biotechnology. He is the author of more than 100 peer-reviewed scientific publications, book chapters, and reviews, and 38 issued U.S. and foreign patents.